Stock events for Editas Medicine, Inc. (EDIT)
Editas Medicine's stock price has experienced volatility over the past six months, trading between $4.54 and $0.91. The stock has seen a decrease of 21.57% in the past six months. Key events include the announcement of third-quarter 2025 results and business updates in November 2025, presentation of preclinical data for EDIT-401 at ESGCT and AHA, and the CEO selling a small amount of stock in March 2026. Short interest in Editas Medicine recently increased by 2.47%, indicating decreasing investor sentiment.
Demand Seasonality affecting Editas Medicine, Inc.’s stock price
Information regarding specific demand seasonality for Editas Medicine's products and services is not readily available. The demand for its pipeline candidates is driven by unmet medical needs in specific disease areas and the progress and success of its clinical development programs. Success in clinical trials and regulatory approvals would be the main drivers of future commercial demand.
Overview of Editas Medicine, Inc.’s business
Editas Medicine, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines using CRISPR gene editing technology. The company uses CRISPR/Cas9 and CRISPR/Cas12a platforms to correct disease-causing genetic mutations. Its product pipeline includes EDIT-101 for Leber congenital amaurosis type 10, EDIT-301 for severe hematologic diseases, EDIT-401 for cardiometabolic diseases, and oncology programs modifying immune cells to enhance anti-tumor activity. The company plans to file Investigational New Drug (IND) and Clinical Trial Application (CTA) submissions for EDIT-401 by mid-2026.
EDIT’s Geographic footprint
Editas Medicine's primary operational footprint is in the United States, with locations in Cambridge, Massachusetts, and Boulder, Colorado. While its direct office presence is US-based, the company's reach extends globally through its clinical trials and collaborations.
EDIT Corporate Image Assessment
Editas Medicine is regarded as a pioneering gene editing company focused on developing transformative medicines. Its reputation is built on translating CRISPR genome editing systems into a pipeline of medicines. Promising preclinical results for EDIT-401 have positively contributed to its scientific standing. However, financial challenges and a revolving door at the CEO level can impact investor sentiment.
Ownership
Editas Medicine has a mixed ownership structure comprising institutional, individual, and insider investors. As of late 2025, individual investors collectively owned about 53% of the company, while institutional investors held around 47% of the total shares outstanding. More recent data from March 2026 indicates that 71.90% of the stock is held by institutions, and 2.10% by insiders. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Insiders own less than 1% of the company.
